Data on ED, LUTS offer unique opportunity for urologists
October 1st 2006Several studies presented at the 2006 AUA annual meeting provided evidence of a relationship between erectile dysfunction and lower urinary tract symptoms, with some data showing that treatment of LUTS will improve ED and vice versa. Treating multiple conditions at once means that patients may be able to receive better overall care, but physicians must avoid simply treating symptoms and take a more global approach to patient care, according to Steven A. Kaplan, MD. In this Urology Times interview, Dr. Kaplan, professor of urology and chief of the Institute of Bladder and Prostate Health at Weill Cornell Medical College, Cornell University, New York, discusses current findings on the association between ED and LUTS and their implications for patient management. He was interviewed by UT Editorial Consultant Philip M. Hanno, MD, MPH, professor of urology at the University of Pennsylvania, Philadelphia.
Groups issue advisory about alpha-blockers, iris syndrome
October 1st 2006Linthicum, MD-AUA has partnered with two leading ophthalmology groups to raise awareness that individuals with past or present use of an alpha-1 blocker may develop a condition known as intraoperative floppy iris syndrome (IFIS) while undergoing cataract surgery and should inform their ophthalmologist about such medication use so that appropriate surgical techniques can be used.
Radical nephrectomy may be risk factor for kidney disease
September 21st 2006Kidney cancer patients with two otherwise healthy kidneys who underwent partial nephrectomy to remove a small cancer developed chronic kidney disease at a rate one-third lower than patients who underwent radical nephrectomy, reported researchers from Memorial Sloan-Kettering Cancer Center in New York.
Prostate cancer patients sought for database study
September 21st 2006Men with prostate cancer and their spouses/significant others are being sought for a joint study being conducted by two Los Angeles-area medical centers as part of a collaborative effort to better understand the genetics of the disease.
Therapy cures VUR in more than 90% of children
September 7th 2006Treatment with hyaluronic acid/dextranomer gel (Deflux) showed a cure rate of more than 90% in children with vesicoureteral reflux, with 82.2% showing resolution after just one treatment, according to a study published last month in Pediatrics (2006; 118:698-703).
Trial will examine drug's effect in delaying prostate cancer surgery
September 7th 2006GlaxoSmithKline has initiated REDEEM, a multicenter, North American clinical trial designed to determine whether the 5-alpha-reductase inhibitor dutasteride (Avodart) can delay or prevent prostate surgery or radiation, shrink prostate cancer tumors, and lessen severity of tumors in men with low-grade prostate cancer.
Groups issue advisory about alpha-blockers and cataract surgery complications
September 7th 2006AUA, the American Society of Cataract and Refractive Surgery, and the American Academy of Ophthalmology have advised patients taking alpha-blockers for BPH treatment to inform their eye surgeon about the drugs before undergoing eye surgery.
Studies document new agent's efficacy in advanced RCC
September 1st 2006Atlanta-Two recent studies have provided promising outcomes data on sorafenib tosylate (Nexavar), both as a second-line therapy and potentially as first-line treatment in patients with advanced renal cell carcinoma, researchers reported at the American Society of Clinical Oncology annual meeting here.